NEW YORK--(BUSINESS WIRE)--Ataraxis AI, the leading AI precision medicine company, today emerged from stealth with $4 million in seed financing co-led by Giant Ventures and Obvious Ventures. The funding, raised in 2023 but announced for the first time today, has enabled Ataraxis to develop groundbreaking AI-powered diagnostic tests that significantly enhance the prediction of patient outcomes and enable more precise, personalized treatments.

纽约--（商业新闻短讯）--领先的人工智能精密药物公司Ataraxis AI今天从隐形中脱颖而出，拥有400万美元的种子融资，由大型风险投资公司和明显的风险投资公司共同领导。该资金于2023年筹集，但今天首次宣布，使Ataraxis能够开发开创性的人工智能诊断测试，显着增强对患者预后的预测，并实现更精确，个性化的治疗。

The company also unveiled its first offering, Ataraxis Breast – the world’s first AI-native prognostic/predictive test for breast cancer and the most advanced clinically validated test available..

该公司还推出了第一款产品Ataraxis Breast，这是世界上第一款人工智能乳腺癌预后/预测测试，也是目前最先进的临床验证测试。

Molecular diagnostic tests have historically been considered the industry standard for personalized treatment selection, particularly in oncology. However, these tests rely on processing physical tissue and have significant limitations such as suboptimal accuracy, long development cycles, limited scope, and high costs..

。然而，这些测试依赖于处理物理组织，并且具有显着的局限性，例如不理想的准确性，长的开发周期，有限的范围和高成本。

To solve these challenges, Jan Witowski, MD, PhD, and Krzysztof Geras, PhD, founded Ataraxis AI. The company is developing multi-modal AI foundation models and diagnostic tests that predict patients' risk of cancer occurrence and outcomes, allowing providers to personalize treatments that will be most effective for each patient.

为了解决这些挑战，医学博士Jan Witowski和博士Krzysztof Geras创立了Ataraxis AI。该公司正在开发多模式AI基础模型和诊断测试，以预测患者发生癌症的风险和结果，使提供者能够个性化治疗，对每个患者最有效。

Ataraxis plans to develop diagnostic tests for at least 50% of the 26 million new cancer patients expected to be diagnosed globally by 2030..

Ataraxis计划为预计到2030年在全球确诊的2600万新癌症患者中的至少50%开发诊断测试。

By creating this new category of tests, Ataraxis is transforming the future of cancer care, giving doctors powerful insights into their patients' health. This groundbreaking approach enables healthcare providers to craft highly personalized treatment plans, ensuring that every patient receives the most effective care possible..

通过创建这种新的测试类别，Ataraxis正在改变癌症护理的未来，为医生提供对患者健康的有力见解。这种开创性的方法使医疗保健提供者能够制定高度个性化的治疗计划，确保每位患者都能获得尽可能有效的护理。

“As a medical doctor, I was initially excited about the potential of precision medicine, having seen firsthand the urgent need for solutions to help hundreds of thousands of patients. Unfortunately, over the past decade, that promise has largely gone unfulfilled,” said Jan Witowski, co-founder and CEO of Ataraxis.

Ataraxis联合创始人兼首席执行官扬·维托夫斯基（JanWitowski）表示：“作为一名医生，我最初对精准医学的潜力感到兴奋，因为我亲眼目睹了帮助数十万患者的解决方案的迫切需求。不幸的是，在过去十年中，这一承诺基本上没有实现。”

“Building on our advisor Yann LeCun’s pioneering work in modern AI, we are establishing a completely new category of tests that will phase out molecular diagnostics, transitioning the industry to AI precision medicine—an approach that is more accurate, efficient, and cost-effective, with the potential to save countless more lives.”.

“在我们的顾问Yann LeCun在现代人工智能领域的开创性工作的基础上，我们正在建立一个全新的测试类别，将逐步淘汰分子诊断，将行业转变为人工智能精密医学-一种更准确，更高效，更具成本效益的方法，有可能挽救无数更多的生命。”

To enable this new era of AI precision medicine Ataraxis has developed Kestrel, a foundation AI model for digital pathology that outperforms all existing state-of-the-art pathology foundation models. The Kestrel model discovers novel features correlated with patient outcomes that are often more complex than what can be understood by human experts, including physicians, and span all disease types.

为了实现人工智能精准医学的新时代，Ataraxis开发了Kestrel，这是一种用于数字病理学的基础人工智能模型，其性能优于所有现有的最先进的病理学基础模型。红隼模型发现了与患者结局相关的新特征，这些特征通常比包括医生在内的人类专家所能理解的更为复杂，并且涵盖了所有疾病类型。

Using these findings, Ataraxis can develop multi-modal diagnostic tests for any indication that continuously improve in accuracy, can be applied quickly to any clinical scenario, have a wide scope, and are delivered in a software-like manner..

利用这些发现，Ataraxis可以针对任何适应症开发多模式诊断测试，这些适应症的准确性不断提高，可以快速应用于任何临床情况，范围广泛，并以类似软件的方式交付。

“Ataraxis has created a breast cancer outcome prediction system that produces personalized predictions with record-breaking accuracy. They are leveraging the latest developments in deep learning and AI such as self-supervised training and joint embedding architectures. Beyond this success, Ataraxis has an ambitious vision to bring about the transformative potential of AI in healthcare,” said Yann LeCun, Jacob T.

“Ataraxis创建了一个乳腺癌结果预测系统，该系统可以产生具有创纪录准确性的个性化预测。他们正在利用深度学习和人工智能的最新发展，例如自我监督训练和联合嵌入架构。除了这一成功，Ataraxis还有一个雄心勃勃的愿景，即在医疗保健领域发挥人工智能的变革潜力，”雅各布·T·扬·勒昆（YannLecun）说。

Schwartz Professor of Computer Science at NYU, Chief AI Scientist at Meta, and Turing Award Laureate..

纽约大学计算机科学教授、Meta首席人工智能科学家和图灵奖得主。

Using Kestrel, the company has created its first clinical diagnostic test, Ataraxis Breast. The test has initially been clinically validated in a multi-site study testing over 7,500 patients from 15 institutions across 3 continents, with plans for further validation. The results were published in a preprint publication and demonstrate that Ataraxis Breast greatly outperforms the current standard of care in breast cancer treatment selection, as evidenced by:.

使用红隼，该公司创建了其第一个临床诊断测试，Ataraxis Breast。该测试最初已在来自3大洲15个机构的7500多名患者的多地点研究测试中进行了临床验证，并计划进一步验证。结果发表在预印本出版物中，并证明Ataraxis Breast在乳腺癌治疗选择方面大大优于当前的护理标准，如：

30% higher accuracy in predicting cancer recurrence than the standard of care molecular diagnostic assay.

预测癌症复发的准确性比标准护理分子诊断分析高30%。

Reclassification of “intermediate risk” patients into low- or high-risk groups, helping more patients potentially avoid chemotherapy.

将“中等风险”患者重新分类为低风险或高风险组，帮助更多患者避免化疗。

Generalization across all cancer subtypes, expanding testing to 100,000 additional patients annually in the US alone.

在所有癌症亚型中推广，仅在美国每年就将检测范围扩大到100000名额外患者。

Answering new, high-value clinical questions (e.g. if patients who have undergone chemoendocrine therapy can benefit from CDK4/6 inhibitors).

回答新的高价值临床问题（例如，接受化学内分泌治疗的患者是否可以从CDK4/6抑制剂中受益）。

Best-in-class turnaround times and cost structure.

一流的周转时间和成本结构。

“Ataraxis has the potential to revolutionize cancer treatment, pioneering in a new era of AI-driven precision medicine that will elevate patient care and outcomes,” said Madelene Larsson, Principal at Giant Ventures. “Tissue biopsies provide one of the richest sources of medical data, and Jan and his team have developed a transformative approach using multi-modal AI models to help doctors identify treatment options beyond chemotherapy,” Rohan Ganesh, Partner at Obvious Ventures, added..

Giant Ventures负责人马德琳·拉尔森（MadeleneLarsson）表示：“Ataraxis有可能彻底改变癌症治疗，开创人工智能驱动的精准医学的新时代，从而提高患者护理和预后。”。“组织活检提供了最丰富的医学数据来源之一，Jan和他的团队已经开发出一种变革性方法，使用多模式人工智能模型来帮助医生确定化疗以外的治疗选择，”Opsient Ventures的合伙人Rohan Ganesh补充道。

Patients from several of the world’s leading health systems and cancer care centers have participated in the validation of Ataraxis Breast, including Gundersen Health System, Karmanos Cancer Institute, NYU Langone Health, and Providence. The company plans to continue expanding its partnerships to make the test available to as many patients as possible..

来自多个世界领先的卫生系统和癌症护理中心的患者参与了Ataraxis乳房的验证，包括Gundersen卫生系统，Karmanos癌症研究所，NYU Langone health和Providence。该公司计划继续扩大合作伙伴关系，使尽可能多的患者可以使用该测试。

About Ataraxis AI

关于Ataraxis AI

Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of artificial intelligence. Backed by leading investors Giant Ventures and Obvious Ventures, the company is addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data.

Ataraxis是一家人工智能精准医学公司，通过人工智能的力量改变癌症诊断和患者预后。在领先投资者的支持下，该公司正在通过前沿的基础模型和多模式数据，解决癌症预后和治疗选择方面以前无法解决的问题。

Ataraxis’ first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai..

Ataraxis的第一个经过临床验证的产品Ataraxis Breast是世界上第一个针对乳腺癌的AI天然预后/预测测试，其准确性高于标准护理基因组检测。要了解更多信息，请访问ataraxis.ai。